Mahsa Motavaf

Dr. Mahsa Motavaf


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
STShima Tavakol
Shima Tavakol
MAMilad Ashrafizadeh
Milad Ashrafizadeh
SDShuo Deng
Shuo Deng
MAMaryam Azarian
Maryam Azarian
AAAsghar Abdoli
Asghar Abdoli
Alan Prem KumarAlan Prem Kumar
Alan Prem Kumar
Autophagy modulation is considered to be a promising programmed cell death mechanism to prevent and cure a great number of disorders and diseases. The crucial step in designing an effective therapeutic approach is to understand the correct and accurate causes of diseases and to understand whether autophagy plays a cytoprotective or cytotoxic/cytostatic role in the progression and prevention of disease. This knowledge will help scientists find approaches to manipulate tumor and pathologic cells in order to enhance cellular sensitivity to therapeutics and treat them. Although some conventional therapeutics suffer from poor solubility, bioavailability and controlled release mechanisms, it appears that novel nanoplatforms overcome these obstacles and have led to the design of a theranostic-controlled drug release system with high solubility and active targeting and stimuli-responsive potentials. In this review, we discuss autophagy modulators-related signaling pathways and some of the drug delivery strategies that have been applied to the field of therapeutic application of autophagy modulators. Moreover, we describe how therapeutics will target various steps of the autophagic machinery. Furthermore, nano drug delivery platforms for autophagy targeting and co-delivery of autophagy modulators with chemotherapeutics/siRNA, are also discussed.

30 January 2016 in Iranian Red Crescent Medical Journal
Verified
Journal Article
Open access
PDF file
KPKazem Parivar
Kazem Parivar
FFFatemeh Malekvand Fard
Fatemeh Malekvand Fard
MBMahdieh Bayat
Mahdieh Bayat
SASeyed Moayed Alavian
Seyed Moayed Alavian
MMMahsa Motavaf
Mahsa Motavaf
Background: Because of their unique magnetic properties, Fe3O4 nanoparticles (Fe3O4-NPs) have extensive applications in various biomedical aspects. Investigation of the possible adverse aspects of these particles has lagged far behind their fast growing application. Objectives: The current study aimed to evaluate the toxicity of Fe3O4-NPs in the liver of mice. Materials and Methods: In the present clinical trial, 90 BALB/c mice were randomly divided in 15 groups. Five control groups were fed by usual water and food. Five placebo groups were gavaged with physiological serum in doses of 25, 50, 75, 150, and 300 micrograms per gram of body weight (μg/gr). Five experimental groups were gavaged with Fe3O4-NPs, in doses of 25, 50, 75, 150, and 300 μg/gr. This pattern was repeated every other day, for 3 days. Then, the levels of liver enzymes [alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)] were compared between these groups. The histological alterations of livers were examined, as well. For statistical analysis, Kruskal-Wallis and Mann-Whitney, with type I Bonferroni correction, as post-hoc, have been used. Results: The administration of 150 and 300 μg/gr doses of Fe3O4-NPs were associated with significant elevation in liver enzymes, compared to controls (P < 0.0001). Furthermore, the histopathological effects were observed in the liver tissue of these groups. However, in groups treated with lower doses of Fe3O4-NPs, no significant adverse effect was observed. Conclusions: Based on our results, the administration of Fe3O4-NPs causes dose dependent adverse effects on liver. Keywords: Ferric Oxide; Nanoparticles; Aspartate Aminotransferases; Alanine Transaminases; Alkaline Phosphatase; Hepatocytes; Liver

1 June 2016
Verified
Journal Article
Closed access
SSSaeid Safari
Saeid Safari
FMF. Malekvandfard
F. Malekvandfard
SBS. Babashah
S. Babashah
AAAzin Alizadehasl
Azin Alizadehasl
MSM. Sadeghizadeh
M. Sadeghizadeh
MMMahsa Motavaf
Mahsa Motavaf

28 February 2019 in Biomedical Research and Therapy
Verified
Journal Article
Open access
PDF file
MMMarjan Mokhtare
Marjan Mokhtare
AZAhmad Darvishi Zeidabadi
Ahmad Darvishi Zeidabadi
MBMansour Bahardoust
Mansour Bahardoust
SSSaeid Safari
Saeid Safari
MBMitra Barati
Mitra Barati
MMMahsa Motavaf
Mahsa Motavaf
Introduction: Hepatitis C virus (HCV) infection affects almost 180 million people around the world. Even though the development of direct acting antivirals (DAAs) has significantly improved the treatment responses to HCV infection, treatment with pegylated interferon (PegIFN) in combination with ribavirin is considered the standard of care (SOC) for chronic HCV infection treatment in countries with limited medical resources. Considering the inhibitory effect of vitamin B12 on HCV replication, we have evaluated the effect of vitamin B12 supplementation along with SOC on treatment outcomes in patients with chronic HCV infection, who were antiviral treatment-naive. Methods: In this regard, seventy-four HCV-infected patients, naïve to antiviral therapy, were randomly assigned to receive SOC or SOC in addition to vitamin B12 (SOC + B12). Viral response was evaluated at 4, 12, 24 and 48 weeks following the initiation of viral treatment and at 24 weeks after completing the treatment. Genotyping of the interleukin 28B (IL28B) polymorphisms was also performed. Demographic characteristics, clinical findings, fibroscan results and drug adverse effects were recorded. Results: Our findings showed that rapid viral response was not significantly different between the two groups; however, the rates of complete early viral response (cEVR) (p=0.033), end-of-treatment viral response (ETVR) (p=0.001) and sustained virologic response (SVR) (p=0.0001) were significantly higher in SOC + B12 patients compared to SOC patients. Besides, in SOC + B12 patients, those with a higher baseline viral load and carriers of IL28B CC genotype showed significantly higher rate of SVR. Conclusion: In conclusion, the addition of vitamin B12 significantly improved the rate of SVR in HCV-infected patients, who were naïve to antiviral therapy. As this treatment regimen is safe and inexpensive, it proposes an option for improving the effectiveness of the HCV treatment with SOC, particularly in resource-limited settings.

29 July 2017 in Journal of Human Genetics and Genomics
Verified
Journal Article
Open access
PDF file
LZLeila Zare
Leila Zare
MMMahsa Motavaf
Mahsa Motavaf
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Currently a single accurate method for diagnosis of MS is lacking. Exosomes are small membranous transport vesicles providing a means of cell-to-cell communication by transporting their cargo. Considering accumulating evidence emphasizing potential role of exosomes in the regulation of the immune system, circulating exosomes represent promising candidate biomarkers for a this diseases. Keywords: Exosome; microRNAs; Multiple Sclerosis